慢性鼻炎与鼻多重症的生物学:当前的景观和未来的方向
Jerlon Chiu1, Judd Fastenberg2,3, Charles Tong2,3
1Division of Otolaryngology-Head & Neck Surgery Stony Brook University Stony Brook New York USA.
Laryngoscope investigative otolaryngology
|October 20, 2025
概括
针对2型炎症的生物疗法为患有鼻多重症 (CRSwNP) 的慢性鼻炎患者提供了新的希望. 虽然有效,但成本和选择生物标志物等挑战需要进一步研究以实现个性化治疗.
科学领域:
- 免疫学 免疫学 免疫学
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 药理学 药理学是指药理学的学科.
背景情况:
- 带鼻多重症的慢性鼻炎 (CRSwNP) 是一种2型炎症状况,通常对传统疗法有抗性.
- 针对关键的2型细胞因子 (IL-4,IL-5,IL-13) 和IgE的生物药物在治疗严重或复发性CRSwNP方面取得了重大进展.
研究的目的:
- 审查目前关于CRSwNP生物疗法的证据.
- 讨论CRSwNP.生物治疗中的挑战,未来方向和精准医学机会.
主要方法:
- 对CRSwNP生物疗法的当前文献的综述.
- 对FDA批准的生物药物 (杜皮卢马布,奥马利祖马布,梅波利祖马布) 和新兴治疗方法的分析.
- 讨论临床试验结果,指导方针建议和剩余的挑战.
主要成果:
- 生物药物有效地降低了多体大小,改善了症状,并提高了2型炎症CRSwNP患者的生活质量.
- 目前的指导方针支持选择对标准护理反应不足的患者使用生物药物.
- 挑战包括高成本,治疗持续时间的不确定性,缺乏比较数据和生物标志物需求.
结论:
- 生物学已经改变了CRSwNP的管理,但个性化的选择和与手术的整合是关键.
- 对非2型炎症和解决当前治疗局限性的进一步研究是必要的.
- 使用生物标志物的精准医学方法将优化CRSwNP患者的治疗结果.
相关概念视频
Drugs Used in Lower Respiratory Disorders: Overview
1.0K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.0K
Drug Products: Biologics, Biosimilars and Interchangeables
230
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
230
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
484
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
484
Inflammatory Bowel Disease IV: Pharmacological Management
496
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
496
Microorganisms in Medicine and Therapeutics
936
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
936
Drugs Used in Upper Respiratory Disorders: Overview
622
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
622


